

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-36. (Canceled)

37. (Currently amended) An isolated polypeptide comprising SEQ ID NO:4, wherein said polypeptide binds ~~at least one of human IL-13 and human IL-4.~~

38-41. (Canceled)

42. (Previously presented) The isolated polypeptide of claim 37 wherein said polypeptide is glycosylated.

43. (Previously presented) The isolated polypeptide of claim 37 wherein said polypeptide is unglycosylated.

44-46. (Canceled)

47. (Previously presented) A composition comprising the isolated polypeptide of Claim 37 and a pharmaceutically acceptable carrier.

48-51. (Canceled)

52. (New) An isolated polypeptide comprising amino acids 28-426 of SEQ ID NO: 4 or comprising an amino acid sequence having at least 95% identity with amino acids 28-426 of SEQ ID NO: 4, wherein said polypeptide binds IL-13.

53. (New) An isolated polypeptide comprising amino acids 28-342 of SEQ ID NO: 4 or comprising an amino acid sequence having at least 95% identity with amino acids 28-342 of SEQ ID NO: 4, wherein said polypeptide binds IL-13.

54. (New) A composition comprising the isolated polypeptide of claim 52.

55. (New) A composition comprising the isolated polypeptide of claim 53.